Effects of exendin-4 on islets from type 2 diabetes patients

Diabetes Obes Metab. 2008 Jun;10(6):515-9. doi: 10.1111/j.1463-1326.2007.00838.x. Epub 2008 Jan 14.

Abstract

Exendin-4 is a dipeptidyl peptidase IV (DPP-IV)-resistant glucagon-like peptide 1 (GLP-1) mimetic and its synthetic counterpart, exenatide, is being used in the therapy of type 2 diabetes (T2DM). No information, however, is currently available as for the direct action of exendin-4 on human T2DM islets. In the present study, we exposed pancreatic islets prepared from non-diabetic and T2DM subjects to exendin-4 for 48 h and found that the compound had several, direct beneficial actions on insulin secretion and the expression of genes involved in beta-cell function and differentiation.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Case-Control Studies
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Exenatide
  • Female
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • Insulin / metabolism
  • Insulin Secretion
  • Insulin-Secreting Cells / drug effects
  • Islets of Langerhans / drug effects*
  • Male
  • Middle Aged
  • Peptides / pharmacology*
  • Venoms / pharmacology*

Substances

  • Hypoglycemic Agents
  • Insulin
  • Peptides
  • Venoms
  • Exenatide